Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. - Wikidata - awgldk - TriplyDB

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.

http://www.wikidata.org/entity/Q38018370

about

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.Single-dose intranasal treatment with DEF201 (adenovirus vectored consensus interferon) prevents lethal disease due to Rift Valley fever virus challenge.Harnessing the immune system for the treatment of melanoma: current status and future prospects.Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo.Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors.

P2860

Q30357731-31EC456F-087E-45F4-8813-ED7ADC04E840 Q37120262-85BBFC6D-A996-4DF9-94FE-1A172EDA634F Q37412789-558D84EB-718C-4EA7-BD02-696112550FA1 Q37673160-977C353E-07A1-4B04-9F9D-D3C470594D22 Q38806243-46102DB2-7873-4755-B064-0AE8389F696E Q39004668-90B61A33-6808-4BD7-A1E9-12AA7330BE04 Q40705563-5792AB9D-BF33-4A98-8BE8-B45A0EF52453 Q42378527-C8FD982F-01FF-4250-A232-6AB38124BACF Q55502689-210AD61C-8163-4658-AEA1-35046EF96132

P2860

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.

http://www.wikidata.org/entity/Q38018370

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.

@en

type

label

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.

@en

prefLabel

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.

@en

P1433

Q38018370-8AF62444-4935-4AD2-8CE6-AB2DA588A9D9

P1476

Q38018370-D75B106B-85EC-4E92-976E-470838B1AB41

P2093

Q38018370-67D948F5-04A1-4CF7-B638-C9E9213CD814

Q38018370-67ECF574-6054-4801-A0C1-CA247A25C7EC

Q38018370-7BE7B5D4-B092-4617-ABC5-809E7A80009F

Q38018370-8F37187E-57E1-4635-8359-C8DEFEE942D2

Q38018370-AF331F6F-12B0-4ADA-9113-D8A7B413DAC8

Q38018370-BDE17BA3-B46A-4C1C-A2A3-E3960CF64298

Q38018370-DF735613-9B82-4DE2-B576-0BAA601847E1

Q38018370-F65B71B5-57E6-44B4-8031-36C9F43FCF7F

P2860

Q38018370-008B94D0-924A-4121-8CB2-041485C79783

Q38018370-16F8606C-75F9-4854-A9CE-7C612539A34E

Q38018370-35EC686B-5035-4501-A4A3-E54608FABB53

Q38018370-44AA56EC-DE9D-4552-947B-D397A9F3F390

Q38018370-5C0C0B5E-3D68-4796-9E01-01FCC0C1D12A

Q38018370-8F4019E6-E7EB-47E9-8246-21EDBE00BCCF

Q38018370-A627EB4B-D3BF-47B9-9DD8-48AFC83A488A

Q38018370-A8175AC7-AABC-4352-B405-583F4F879492

Q38018370-A94EC7D3-2C9D-471D-AC76-85EA8F6CFCEA

Q38018370-AC3044B1-4CDC-429C-BB26-8F1FF893CB2A

P304

Q38018370-6BF9C10D-CA16-4415-A79E-6B978FCDD6A0

P31

Q38018370-2284C8C8-511B-48E3-9EB6-3E9294CD0F57

P356

Q38018370-58F6FBCA-AE11-4ACE-A39A-478AB283BCE8

P407

Q38018370-CBFC0BFD-48F2-428D-BC88-055C426D4F31

P433

Q38018370-D173FAFD-D941-429F-98D6-9BB896CBF8ED

P478

Q38018370-F7E0BBC9-E95C-47CE-B6A7-302077E9A212

P50

Q38018370-91ABA11D-B48A-4FEC-AFC9-86AF30CC29AA

Q38018370-B8142820-8E59-4452-87BC-46FA173FC217

P577

Q38018370-7B081BA5-4340-4726-BA65-14F2B0EAA0EF

P698

Q38018370-5261EE5B-1D55-4EB8-A4A3-1BDA73200C6C

P356

14712598.2012.694421

P1433

Expert Opinion on Biological Therapy

P1476

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.

@en

P2093

Adil Daud

http://www.w3.org/2001/XMLSchema#string

Alexander M M Eggermont

http://www.w3.org/2001/XMLSchema#string

Axel Hauschild

http://www.w3.org/2001/XMLSchema#string

Christopher Soon

http://www.w3.org/2001/XMLSchema#string

Claus Garbe

http://www.w3.org/2001/XMLSchema#string

Jean Jacques Grob

http://www.w3.org/2001/XMLSchema#string

Reinhard Dummer

http://www.w3.org/2001/XMLSchema#string

Wen-Jen Hwu

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

PEGylation, successful approach to drug delivery

Final version of 2009 AJCC melanoma staging and classification

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.

Adjuvant therapy: melanoma

P304

1087-1099

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2012.694421

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Eggermont

Jean-Jacques Grob

P577

2012-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22694288

http://www.w3.org/2001/XMLSchema#string